Douglas R Martin Selected Research

GM1 Gangliosidosis (Gangliosidosis GM1)

1/2022	Intravenous delivery of adeno-associated viral gene therapy in feline GM1 gangliosidosis.
1/2021	GM1 Gangliosidosis: Mechanisms and Management.
12/2017	Polyethylene glycol-b-poly(lactic acid) polymersomes as vehicles for enzyme replacement therapy.
9/2017	Lipidomic Evaluation of Feline Neurologic Disease after AAV Gene Therapy.
1/2017	Novel Biomarkers of Human GM1 Gangliosidosis Reflect the Clinical Efficacy of Gene Therapy in a Feline Model.
4/2014	Sustained normalization of neurological disease after intracranial gene therapy in a feline model.
9/2012	Evaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy.
6/2008	Generation and characterization of recombinant feline beta-galactosidase for preclinical enzyme replacement therapy studies in GM1 gangliosidosis.
6/2008	Molecular consequences of the pathogenic mutation in feline GM1 gangliosidosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Douglas R Martin Research Topics

Disease

9	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 11/2007
9	GM1 Gangliosidosis (Gangliosidosis GM1) 01/2022 - 06/2008
9	Sandhoff Disease (Sandhoff's Disease) 01/2021 - 03/2009
6	Lysosomal Storage Diseases (Lysosomal Storage Disease) 01/2021 - 05/2009
6	GM2 Gangliosidoses (GM2 Gangliosidosis) 01/2020 - 11/2005
4	Tay-Sachs Disease 01/2022 - 01/2015
4	Gangliosidoses (Gangliosidosis) 01/2016 - 05/2004
3	Disease Progression 01/2022 - 01/2015
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	Obesity 01/2022
1	Seizures (Absence Seizure) 01/2022
1	Overweight 01/2022
1	Neoplasms (Cancer) 01/2022
1	Nervous System Diseases (Neurological Disorders) 01/2022
1	Insulin Resistance 01/2022
1	Body Weight (Weight, Body) 01/2022
1	Gliosis 12/2020
1	Type 2 Diabetes Mellitus (MODY) 01/2020
1	Infertility (Sterility) 01/2020
1	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 01/2020
1	Alzheimer Disease (Alzheimer's Disease) 01/2020
1	Stroke (Strokes) 04/2014
1	Parkinson Disease (Parkinson's Disease) 04/2014
1	Ataxia (Dyssynergia) 11/2005

Drug/Important Bio-Agent (IBA)

10	EnzymesIBA 01/2021 - 06/2008
7	G(M2) Ganglioside (Ganglioside GM2)IBA 01/2021 - 05/2004
6	GalactosidasesIBA 01/2022 - 09/2012
3	LipidsIBA 01/2022 - 03/2009
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2015
3	Hexosaminidases (Hexosaminidase)IBA 01/2020 - 05/2009
3	GangliosidesIBA 01/2020 - 01/2014
3	beta-N-AcetylhexosaminidasesIBA 05/2009 - 05/2004
2	Hexosaminidase A (Hex A)IBA 01/2022 - 01/2018
2	bis(monoacylglyceryl)phosphateIBA 01/2020 - 05/2015
2	G(M1) GangliosideIBA 09/2012 - 06/2008
2	Proteins (Proteins, Gene)FDA Link 06/2008 - 05/2004
2	Complementary DNA (cDNA)IBA 06/2008 - 06/2008
2	beta-Galactosidase (Lactaid)IBA 06/2008 - 06/2008
1	Indicators and Reagents (Reagents)IBA 01/2022
1	PrebioticsIBA 01/2022
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 12/2020
1	Islet Amyloid PolypeptideIBA 01/2020
1	OligosaccharidesIBA 01/2020
1	Peptides (Polypeptides)IBA 01/2020
1	Polysaccharides (Glycans)IBA 01/2020
1	VaccinesIBA 01/2020
1	Amyloid (Amyloid Fibrils)IBA 01/2020
1	pramlintide (Symlin)FDA Link 01/2020
1	feralIBA 01/2020
1	SphingolipidsIBA 09/2017
1	GlycolipidsIBA 09/2017
1	Lysergic Acid Diethylamide (LSD)IBA 01/2017
1	Glycoside Hydrolases (Endoglycosidases)IBA 01/2016
1	Fatty Acids (Saturated Fatty Acids)IBA 05/2015
1	GlycosphingolipidsIBA 03/2009
1	Glucose (Dextrose)FDA LinkGeneric 06/2008
1	Protein Disulfide-IsomerasesIBA 06/2008
1	Arginine (L-Arginine)FDA Link 06/2008
1	G(M2) Activator ProteinIBA 11/2005
1	Amino Acids FDA Link 05/2004

Therapy/Procedure

8	Therapeutics 01/2022 - 11/2007
1	Aftercare (After-Treatment) 01/2022
1	Contraception (Birth Control) 01/2020
1	Investigational Therapies (Experimental Therapy) 01/2016
1	Enzyme Replacement Therapy 06/2008
1	Transplantation 11/2007